Les meilleurs podcasts Touchpod (2024)

1
touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? 15:14

7h ago15:14

15:14

touchMDT for touchRESPIRATORY What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidanc…

1
touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? 13:57

8h ago13:57

13:57

touchMDT for touchRESPIRATORY What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights. The…

1
touchMDT for touchRESPIRATORY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? 14:53

8h ago14:53

14:53

touchMDT for touchRESPIRATORY What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and revi…

1
touchMDT for touchONCOLOGY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? 15:14

8h ago15:14

15:14

touchMDT for touchONCOLOGY What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance o…

1
touchMDT for touchONCOLOGY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? 13:57

8h ago13:57

13:57

touchMDT for touchONCOLOGY What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights. The mu…

1
touchMDT for touchONCOLOGY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? 14:53

8h ago14:53

14:53

touchMDT for touchONCOLOGY What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review …

1
Vaccination strategies for pneumococcal disease 33:06

8d ago33:06

33:06

touchEXPERT OPINIONS for touchINFECTIOUS DISEASES In this activity, Prof. Antoni Torres, a leading expert in respiratory infections, discusses the burden of pneumococcal disease in vulnerable patient populations, the evolving landscape of Streptococcus pneumoniae subtypes and the role that next-generation vaccines can play in preventing severe pneu…

1
Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024 52:36

16d ago52:36

52:36

touchCONGRESS for touchONCOLOGY Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joine…

1
Pharmacological management of agitation in Alzheimer's dementia 34:28

20d ago34:28

34:28

touchPANEL DISCUSSION for touchNEUROLOGY Listen to a panel of leading experts discuss best practice in the management of agitation in Alzheimer’s dementia and the potential of new pharmacological approaches that target aspects of the underlying pathophysiology. The experts Prof. Jeffrey Cummings, University of Nevada, Las Vegas, NV, USA Prof. Krist…

1
touchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchRESPIRATORY 35:33

21d ago35:33

35:33

touchIN CONVERSATION for touchRESPIRATORY Listen to Prof. Manreet Kanwar in conversation with Prof. Jean-Luc Vachiéry, two experts in pulmonary arterial hypertension who are practicing in the USA and Belgium, respectively. They respond to questions submitted by the HCP audience and provide expert insights into the diagnosis of pulmonary arterial hy…

1
touchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchCARDIO 35:33

21d ago35:33

35:33

touchIN CONVERSATION for touchCARDIO Listen to Prof. Manreet Kanwar in conversation with Prof. Jean-Luc Vachiéry, two experts in pulmonary arterial hypertension who are practicing in the USA and Belgium, respectively. They respond to questions submitted by the HCP audience and provide expert insights into the diagnosis of pulmonary arterial hyperte…

1
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1 -touchONCOLOGY 14:12

28d ago14:12

14:12

touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Me…

1
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2 -touchONCOLOGY 15:59

28d ago15:59

15:59

touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Me…

1
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1 -touchRESPIRATORY 14:12

28d ago14:12

14:12

touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of…

1
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2 -touchRESPIRATORY 15:59

28d ago15:59

15:59

touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of…

1
Targets in early NSCLC: A focus on EGFR-mutant treatment options 16:22

29d ago16:22

16:22

touchFOCUS for touchONCOLOGY Listen to Dr Jennifer Carlisle, an expert in lung cancer, as she answers a series of questions on the targeted perioperative treatment strategies and best practices for patients with resectable and unresectable early-stage EGFR-mutant NSCLC. She also discusses how the evolving treatment landscape impacts biomarker testi…

1
Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024 57:31

1M ago57:31

57:31

touchCONGRESS for touchONCOLOGY Listen to multiple myeloma expert Prof. María-Victoria Mateos review key data for BCMA-targeting agents in the treatment of multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy) and European Hematology Association (EHA) 2024 congresses. Prof. Mateos is then joined by fellow experts …

1
Innovations in glaucoma care: Targeting pathophysiology to expand treatment options 33:45

1M ago33:45

33:45

touchEXPERT OPINIONS for touchOPHTHALMOLOGY Listen to leading experts describe the pathophysiology of open-angle glaucoma and discuss how it is targeted by current and emerging treatment options, while providing insights on how different agents and combinations are used in practice. The experts Angelo P Tanna, MD - Northwestern University Feinberg …

1
Experts in dermatology discuss the latest in treating moderate-to-severe atopic dermatitis in children and adolescents 40:07

1M ago40:07

40:07

touchIN CONVERSATION for touchIMMUNOLOGY Listen to Prof. Diamant Thaçi in conversation with Dr Benjamin Ungar. They respond to questions submitted by the HCP audience and provide their expert insights regarding managing moderate–severe atopic dermatitis (AD) in children and adolescents, including assessing the severity of AD, selecting systemic the…

1
Updates in recurrent/metastatic nasopharyngeal carcinoma: The evolving role of immune checkpoint inhibitors 18:41

2M ago18:41

18:41

touchFOCUS for touchONCOLOGY Listen to Prof. Barbara Burtness as she answers a series of questions focused on the evolving role of immune checkpoint inhibitors in the first- and subsequent-line settings for recurrent/metastatic nasopharyngeal carcinoma. The expert Prof. Barbara Burtness, Yale School of Medicine, New Haven, CT, USA This touchPODCAST…

1
touchMDT – Pruritus in PBC and me: The patient experience – Discussion 1 - touchIMMUNOLOGY 12:49

2M ago12:49

12:49

touchMDT for touchIMMUNOLOGY Pruritus in PBC and me: The patient experience Listen to experts Prof. Gideon Hirschfield and Prof. Sonja Ständer, plus patient advocate Mrs Collette Thain MBE, explore the burden of cholestatic pruritus in patients with primary biliary cholangitis (PBC). The multidisciplinary team and patient advocate: Hepatologist – P…

1
touchMDT – Symptom assessment and monitoring in clinical practice – Discussion 2 - touchIMMUNOLOGY 14:47

2M ago14:47

14:47

touchMDT for touchIMMUNOLOGY Listen to experts Ms Michelle Clayton, Prof. Sonja Ständer and Prof. Gideon Hirschfield discuss the importance of assessing for cholestatic pruritus in patients with primary biliary cholangitis (PBC) and review the tools used in clinical practice. The multidisciplinary team: Nurse – Ms Michelle Clayton St James’ Univers…

1
touchMDT – A comprehensive approach to symptom care in PBC – Discussion 3 - touchIMMUNOLOGY 15:05

2M ago15:05

15:05

touchMDT for touchIMMUNOLOGY Listen to experts Prof. Sonja Ständer, Ms Michelle Clayton, Prof. Gideon Hirschfield and patient advocate, Mrs Collette Thain MBE, discuss individualizing management strategies for patients with cholestatic pruritus and primary biliary cholangitis (PBC), and the importance of patient education and counselling. The multi…

1
touchMDT – A comprehensive approach to symptom care in PBC – Discussion 3 - touchDERMATOLOGY 15:04

2M ago15:04

15:04

touchMDT for touchDERMATOLOGY Listen to experts Prof. Sonja Ständer, Ms Michelle Clayton, Prof. Gideon Hirschfield and patient advocate, Mrs Collette Thain MBE, discuss individualizing management strategies for patients with cholestatic pruritus and primary biliary cholangitis (PBC), and the importance of patient education and counselling. The mult…

1
touchMDT – Symptom assessment and monitoring in clinical practice – Discussion 2 - touchDERMATOLOGY 14:46

2M ago14:46

14:46

touchMDT for touchDERMATOLOGY Listen to experts Ms Michelle Clayton, Prof. Sonja Ständer and Prof. Gideon Hirschfield discuss the importance of assessing for cholestatic pruritus in patients with primary biliary cholangitis (PBC) and review the tools used in clinical practice. The multidisciplinary team: Nurse – Ms Michelle Clayton St James’ Univer…

1
touchMDT – Pruritus in PBC and me: The patient experience – Discussion 1 - touchDERMATOLOGY 12:49

2M ago12:49

12:49

touchMDT for touchDERMATOLOGY Pruritus in PBC and me: The patient experience Listen to experts Prof. Gideon Hirschfield and Prof. Sonja Ständer, plus patient advocate Mrs Collette Thain MBE, explore the burden of cholestatic pruritus in patients with primary biliary cholangitis (PBC). The multidisciplinary team and patient advocate: Hepatologist – …

1
touchMDT – Pruritus in PBC and me: The patient experience – Discussion 1 - touchENDOCRINOLOGY 12:49

2M ago12:49

12:49

touchMDT for touchENDOCRINOLOGY Pruritus in PBC and me: The patient experience Listen to experts Prof. Gideon Hirschfield and Prof. Sonja Ständer, plus patient advocate Mrs Collette Thain MBE, explore the burden of cholestatic pruritus in patients with primary biliary cholangitis (PBC). The multidisciplinary team and patient advocate: Hepatologist …

1
touchMDT – Symptom assessment and monitoring in clinical practice – Discussion 2 - touchENDOCRINOLOGY 14:47

2M ago14:47

14:47

touchMDT for touchENDOCRINOLOGY Listen to experts Ms Michelle Clayton, Prof. Sonja Ständer and Prof. Gideon Hirschfield discuss the importance of assessing for cholestatic pruritus in patients with primary biliary cholangitis (PBC) and review the tools used in clinical practice. The multidisciplinary team: Nurse – Ms Michelle Clayton St James’ Univ…

1
touchMDT – A comprehensive approach to symptom care in PBC – Discussion 3 - touchENDOCRINOLOGY 15:05

2M ago15:05

15:05

touchMDT for touchENDOCRINOLOGY Listen to experts Prof. Sonja Ständer, Ms Michelle Clayton, Prof. Gideon Hirschfield and patient advocate, Mrs Collette Thain MBE, discuss individualizing management strategies for patients with cholestatic pruritus and primary biliary cholangitis (PBC), and the importance of patient education and counselling. The mu…

1
Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease - touchRESPIRATORY 1:06:43

2M ago1:06:43

1:06:43

touchCLINICAL PERSPECTIVES for touchRESPIRATORY Join Dr Helena Yu, course director, as she discusses the unmet needs and research opportunities in metastatic EGFR-mutant and wildtype NSCLC. By exploring key clinical trial data alongside real-world patient cases, healthcare providers will gain valuable insights into how to effectively implement thes…

1
Perspectives on EGFR-mutant and wildtype NSCLC Tailoring treatment advances in late-stage disease - touchONCOLOGY 1:06:43

2M ago1:06:43

1:06:43

touchCLINICAL PERSPECTIVES for touchONCOLOGY Join Dr Helena Yu, course director, as she discusses the unmet needs and research opportunities in metastatic EGFR-mutant and wildtype NSCLC. By exploring key clinical trial data alongside real-world patient cases, healthcare providers will gain valuable insights into how to effectively implement these f…

1
Expanding HER2 horizons: Implications for NSCLC and beyond 41:45

2M ago41:45

41:45

touchPANEL DISCUSSION for touchRESPIRATORY Listen to three experts as they explore tissue-agnostic HER2 targeting in solid tumours, the latest clinical trial data for approved and emerging HER2-targeted therapies in NSCLC, and best practices for testing for HER2 alterations in NSCLC. The experts Dr Razelle Kurzrock - Medical Oncologist, Medical Col…

1
Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP? 53:33

2M ago53:33

53:33

touchCONGRESS for touchONCOLOGY Listen to immune thrombocytopenia (ITP) expert Dr Vickie McDonald review key data presented at the European Hematology Association (EHA) and International Society on Thrombosis and Haemostasis (ISTH) 2024 congresses on the impact and current and future management of ITP. She is joined by two additional leading ITP ex…

1
Continuous glucose monitoring in type 2 diabetes: Overcoming barriers to optimize outcomes 41:33

3M ago41:33

41:33

touchPANEL DISCUSSION for touchENDOCRINOLOGY Listen to a panel of experts discuss the benefits of CGM in patients with T2D, strategies to overcome the barriers to its uptake and how to best support patients in implementing CGM. The experts Prof. Stewart Harris, Western University, London, Ontario, Canada, Dr Anders Carlson, International Diabetes C…

1
Personalizing care within the MDT for patients with early through to advanced RCC 19:36

3M ago19:36

19:36

touchFOCUS for touchONCOLOGY Listen to Prof. Hans Hammers as he answers a series of questions on the application of prognostic markers and clinical data within the multidisciplinary team to personalize care for patients with early stage through to advanced and metastatic RCC. In addition, he responds to questions on the use of effective communicati…

1
Selecting ART: Working with people living with HIV to find the best regimen 39:45

3M ago39:45

39:45

touchIN CONVERSATION for touchINFECTIOUS DISEASES Listen to a conversation between Dr Christoph Boesecke and Dr Tristan Barber, two experts on HIV practising in Germany and the UK. They respond to questions submitted by the HCP audience and provide their insights on best practices for antiretroviral therapy selection for people living with HIV. The…

1
Thyroid eye disease: An evolving continuum of care 38:00

3M ago38:00

38:00

touchPANEL DISCUSSION for touchOPHTHALMOLOGY Listen to a panel of leading experts discuss thyroid eye disease, including the underlying mechanisms, risk factors, symptomatology and burden of disease in affected patients, as well as the process for screening and diagnosing the disease. The experts Dr Andrea Kossler, Stanford University School of Med…

1
Intracranial haemorrhage related to direct oral anticoagulant medications: Latest evidence for reversal strategies 47:09

3M ago47:09

47:09

touchTALKS for touchNEUROLOGY A thrombosis and haemostasis expert shares insights into reversal strategies for patients with direct oral anticoagulant-associated intracranial haemorrhage (DOAC-ICH), including benefits and risks of DOAC use, evidence for DOAC reversal agents and guideline-directed management of the condition. The expert Prof. Dr. me…

1
Expanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approaches 16:01

3M ago16:01

16:01

touchFOCUS for touchONCOLOGY Listen to Dr Dana Chase discuss the role of HER2 as a pan-tumour biomarker and the implications for treatment across various cancer types. The expert Dr Dana Chase - UCLA Health, Los Angeles, CA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from AstraZeneca. T…

1
The path from detection to personalized long-term care for Fabry disease 36:05

4M ago36:05

36:05

touchEXPERT OPINIONS for touchENDOCRINOLOGY Listen to three leading Fabry disease experts discuss early diagnosis, organ monitoring, long-term individualized care and future directions. The experts Prof. Aleš Linhart, Charles University and General University Hospital, Prague, Czech Republic Dr Eric Wallace, University of Alabama at Birmingham Scho…

1
Demystifying virology: The link between the HIV life cycle and ART 37:54

4M ago37:54

37:54

touchEXPERT OPINIONS for touchINFECTIOUS DISEASES Listen to leading experts describe the HIV life cycle, the rationale for multidrug antiretroviral therapy (ART) regimens, mechanisms of ART resistance and how to manage it in people living with HIV. The experts Prof. Anne-Mieke Vandamme - Katholieke Universiteit Leuven, Belgium Prof. José Arribas - …

Podcasts qui valent la peine d'être écoutés

Touchpod Podcasts

Podcasts qui valent la peine d'être écoutés

Guide de référence rapide